Stroke Clinical Trial
— WOEST-3Official title:
What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Having Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention?
The optimal antithrombotic management in patients with coronary artery disease (CAD) and concomitant atrial fibrillation (AF) is unknown. AF patients are treated with oral anticoagulation (OAC) to prevent ischemic stroke and systemic embolism and patients undergoing percutaneous coronary intervention (PCI) are treated with dual antiplatelet therapy (DAPT), i.e. aspirin plus P2Y12 inhibitor, to prevent stent thrombosis (ST) and myocardial infarction (MI). Patients with AF undergoing PCI were traditionally treated with triple antithrombotic therapy (TAT, i.e. OAC plus aspirin and P2Y12 inhibitor) to prevent ischemic complications. However, TAT doubles or even triples the risk of major bleeding complications. More recently, several clinical studies demonstrated that omitting aspirin, a strategy known as dual antithrombotic therapy (DAT) is safer compared to TAT with comparable efficacy. However, pooled evidence from recent meta-analyses suggests that patients treated with DAT are at increased risk of MI and ST. Insights from the AUGUSTUS trial showed that aspirin added to OAC and clopidogrel for 30 days, but not thereafter, resulted in fewer severe ischemic events. This finding emphasizes the relevance of early aspirin administration on ischemic benefit, also reflected in the current ESC guideline. However, because we consider the bleeding risk of TAT unacceptably high, we propose to use a short course of DAPT (omitting OAC for 1 month). There is evidence from the BRIDGE study that a short period of omitting OAC is safe in patients with AF. In this study, these patients are treated with DAPT, which also prevents stroke, albeit not as effective as OAC. This temporary interruption of OAC will allow aspirin treatment in the first month post-PCI where the risk of both bleeding and stent thrombosis is greatest. The WOEST 3 trial is a multicentre, open-label, randomised controlled trial investigating the safety and efficacy of one month DAPT compared to guideline-directed therapy consisting of OAC and P2Y12 inhibitor combined with aspirin up to 30 days. We hypothesise that the use of short course DAPT is superior in bleeding and non-inferior in preventing ischemic events. The primary safety endpoint is major or clinically relevant non-major bleeding as defined by the ISTH at 6 weeks after PCI. The primary efficacy endpoint is a composite of all-cause death, myocardial infarction, stroke, systemic embolism, or stent thrombosis at 6 weeks after PCI.
Status | Recruiting |
Enrollment | 2000 |
Est. completion date | December 1, 2027 |
Est. primary completion date | October 1, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients = 18 years 2. Undergoing successful PCI (either ACS or elective PCI) 3. History of or newly diagnosed (<72 hours after PCI/ACS) atrial fibrillation or flutter with a long-term (= 1 year) indication for OAC Exclusion Criteria: 1. Contra indication to edoxaban, aspirin or all P2Y12 inhibitors 2. Current indication for OAC besides atrial fibrillation/flutter (e.g. venous thromboembolism) 3. <12 months after any stroke 4. CHADSVASc score =7 5. Moderate to severe mitral valve stenosis (AVA =1.5 cm2) 6. Mechanical heart valve prosthesis 7. Intracardiac thrombus or apical aneurysm requiring OAC 8. Poor LV function (LVEF <30%) with proven slow-flow 9. History of intracranial haemorrhage 10. Active bleeding on randomization 11. History of intraocular, spinal, retroperitoneal, or traumatic intra-articular bleeding, unless the causative factor has been permanently resolved 12. Recent (<1 month) gastrointestinal haemorrhage, unless the causative factor has been permanently resolved. 13. Known coagulopathy 14. Severe anaemia requiring blood transfusion or thrombocytopenia <50 × 109/L 15. BMI >40 or bariatric surgery 16. Kidney failure (eGFR <15) 17. Active liver disease (ALT, ASP, AP >3x ULN or active hepatitis A, B or C) 18. Active malignancy excluding non-melanoma skin cancer 19. Life expectancy <1 year 20. Pregnancy or breast-feeding women |
Country | Name | City | State |
---|---|---|---|
Belgium | ASZ Aalst | Aalst | |
Belgium | UZ Antwerpen | Antwerpen | |
Belgium | Imelda Ziekenhuis | Bonheiden | |
Belgium | UZ Brussel | Brussel | |
Belgium | Ziekenhuis Oost-Limburg | Genk | |
Belgium | AZ Maria Middelares Gent | Gent | |
Belgium | Jan Yperman | Ieper | |
Belgium | AZ Groeninge | Kortrijk | |
Belgium | UZ Leuven | Leuven | |
Belgium | AZ Delta | Roeselare | |
Netherlands | Noordwest Ziekenhuisgroep | Alkmaar | |
Netherlands | Amsterdam UMC | Amsterdam | |
Netherlands | OLVG | Amsterdam | |
Netherlands | Hagaziekenhuis | Den Haag | |
Netherlands | Catharina Ziekenhuis | Eindhoven | |
Netherlands | Treant Zorggroep | Emmen | |
Netherlands | Zuyderland Ziekenhuis | Heerlen | |
Netherlands | Tergooi MC | Hilversum | |
Netherlands | St. Antonius Hospital | Nieuwegein | |
Netherlands | Elisabeth Tweesteden Ziekenhuis | Tilburg |
Lead Sponsor | Collaborator |
---|---|
St. Antonius Hospital | Daiichi Sankyo, Inc. |
Belgium, Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Quality of life as assessed by the EuroQol-5D-5L questionnaire | EuroQol-5D-5L questionnaire | 6 weeks, 3 months, 6 months | |
Primary | Primary safety endpoint | Major or clinically relevant non-major bleeding as defined by the International Society of Thrombosis and Haemostasis | 6 weeks | |
Primary | Primary efficacy endpoint | Composite of all-cause death, myocardial infarction, stroke, systemic embolism, or stent thrombosis | 6 weeks | |
Secondary | Bleeding complications | Major or clinically relevant non-major bleeding as defined by the International Society of Thrombosis and Haemostasis | 6 months | |
Secondary | Thrombotic complications | Composite of all-cause death, myocardial infarction, stroke, systemic embolism, or stent thrombosis | 6 months | |
Secondary | Net clinical benefit | Composite of major bleeding, myocardial infarction, stroke, systemic embolism all-cause death and stent thrombosis | 6 weeks, 3 months, 6 months | |
Secondary | Clinical symptom severity | CCS grade | 6 weeks, 3 months, 6 months | |
Secondary | All-cause death | All-cause death as defined by ARC-2 and SCTI | 6 weeks, 3 months, 6 months | |
Secondary | Myocardial infarction | Myocardial infarction as defined by the 4th Universal Definition of Myocardial Infarction | 6 weeks, 3 months, 6 months | |
Secondary | Stroke | Stroke as defined by VARC-2 definitions | 6 weeks, 3 months, 6 months | |
Secondary | Systemic embolism | Systemic embolism according to ENTRUST-AF PCI definition | 6 weeks, 3 months, 6 months | |
Secondary | Stent thrombosis | Stent thrombosis as defined by ARC-2 | 6 weeks, 3 months, 6 months | |
Secondary | Major bleeding | Major bleeding as defined by BARC 3 or 5 | 6 weeks, 3 months, 6 months | |
Secondary | Clinically relevant non-major bleeding | CRNM as defined by BARC 2 | 6 weeks, 3 months, 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Recruiting |
NCT03869138 -
Alternative Therapies for Improving Physical Function in Individuals With Stroke
|
N/A | |
Completed |
NCT04034069 -
Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial
|
N/A | |
Completed |
NCT04101695 -
Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Completed |
NCT00391378 -
Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS)
|
N/A | |
Recruiting |
NCT06204744 -
Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial
|
N/A | |
Active, not recruiting |
NCT06043167 -
Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
|
||
Active, not recruiting |
NCT04535479 -
Dry Needling for Spasticity in Stroke
|
N/A | |
Completed |
NCT03985761 -
Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke
|
N/A | |
Recruiting |
NCT00859885 -
International PFO Consortium
|
N/A | |
Recruiting |
NCT06034119 -
Effects of Voluntary Adjustments During Walking in Participants Post-stroke
|
N/A | |
Completed |
NCT03622411 -
Tablet-based Aphasia Therapy in the Chronic Phase
|
N/A | |
Completed |
NCT01662960 -
Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke
|
N/A | |
Recruiting |
NCT05854485 -
Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke
|
N/A | |
Active, not recruiting |
NCT05520528 -
Impact of Group Participation on Adults With Aphasia
|
N/A | |
Completed |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
Completed |
NCT05805748 -
Serious Game Therapy in Neglect Patients
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05993221 -
Deconstructing Post Stroke Hemiparesis
|